NCT07175233
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 5 more changesShow less
- Trial status changed: Not Yet Recruiting → Active, Not Recruiting
- Primary completion date changed from estimate of Aug 15, 2026 to Sep 23, 2026
- Study completion pushed from Aug 20, 2027 to Nov 30, 2027
- Start date changed from estimate of Oct 27, 2025 to Oct 28, 2025
- Site details revised at 2 of 2 sites
- Minor Study title shortened, about 2 wordsv3
- Minor Study title shortened, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).
Timeframe: At Week 16 (W16)
Arms and interventions
cohort 1- Low dose groupExperimental
cohort 2-Medium dose groupExperimental
cohort 3-High dose groupExperimental
cohort 4- placebo groupPlacebo comparator
Drugs: SIM0278 injection
Other: Placebo
Sites
2 sites in 1 country